Moraxella nonliquefaciens Keratitis Due to Ocular Surface Disease in a Patient Treated with Zanubrutinib for Mantle Cell Lymphoma.
Ori Stern, Haggay Avizemer
✦ AI-curated · Sources linked
Case in brief
A 73-year-old woman on zanubrutinib for mantle cell lymphoma presented with acute eye pain and vision loss. Examination revealed a corneal epithelial defect and stromal infiltrate, alongside bilateral epithelial abnormalities. Cultures identified Moraxella nonliquefaciens. Treatment with topical antimicrobials resolved the infiltrate, but persistent epithelial instability required corticosteroids, leading to significant improvement.
What made this case unusual
The case highlights a potential association between zanubrutinib therapy and ocular surface dysfunction, which may predispose patients to secondary infections, a concern not previously documented.
Diagnostic / clinical pearl
Clinicians should consider the possibility of ocular surface disease in patients receiving zanubrutinib, especially if they present with ocular symptoms.
Why it matters
As the use of immunotherapy increases, awareness of potential ocular toxicities is crucial for timely diagnosis and management, necessitating collaboration between ophthalmologists and oncologists.